Zai Lab
Logotype for Zai Lab Limited

Zai Lab (ZLAB) investor relations material

Zai Lab Q4 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Zai Lab Limited
Q4 2025 earnings summary26 Feb, 2026

Executive summary

  • Achieved total revenue of $460.2M for FY25, up 15% year-over-year, with Q4 revenue at $127.6M, up 17% year-over-year, driven by strong product sales, especially XACDURO and NUZYRA, and commercial execution in China.

  • Advanced global oncology and immunology pipeline, with Zoci moving from IND to global phase III in under two years and aiming for first U.S. approval by 2028; over nine indications in development by 2030.

  • Maintained a robust cash position of $790M at year-end 2025.

  • Focus for 2026 is on execution, pipeline catalysts, and preparation for multiple product launches, with profitability as a key objective.

Financial highlights

  • Product revenue for FY25 reached $457.2M, up 15% year-over-year; Q4 product revenue was $127.1M, up 17%.

  • Notable product growth: XACDURO up 225–593% year-over-year, NUZYRA up 41–45%, ZEJULA up 16%, QINLOCK up 24%, OPTUNE up 19%.

  • Adjusted operating loss for FY25 was $(148.8)M, a 25% improvement from $(199.6)M in FY24; net loss narrowed to $175.5M for the year.

  • R&D expenses declined 6% for the full year to $220.9M; SG&A expenses decreased 7% to $277.6M.

  • Ended the year with $789.6M in cash and equivalents.

Outlook and guidance

  • 2026 is a transition year with continued top-line growth expected, driven by VYVGART, ZEJULA, XACDURO, and new launches like COBENFY and TIVDAK.

  • Multiple pivotal data readouts and regulatory submissions expected in 2026 for key pipeline assets; first U.S. approval targeted by 2028.

  • SG&A and R&D expenses expected to remain flat or grow modestly; focus on operational efficiency and disciplined investment.

  • No full-year guidance provided due to pricing, rebate, and hospital purchasing uncertainties.

XACDURO supply constraints resolution plan
KarXT NRDL inclusion strategy for 2027
Zoci global launch strategy and market focus
Zoci 1L SCLC trial design: doublet vs triplet?
VYVGART cycles per patient: target and progress?
Corporate profitability timeline?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Zai Lab earnings date

Logotype for Zai Lab Limited
Q1 20267 May, 2026
Zai Lab
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Zai Lab earnings date

Logotype for Zai Lab Limited
Q1 20267 May, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Zai Lab Limited is a biopharmaceutical company that focuses on developing and commercializing therapies for oncology, autoimmune disorders, infectious diseases, and neurological conditions. The company operates at the intersection of global research and localized healthcare needs, with a strong presence in China and the United States. Zai Lab has a broad portfolio that includes both licensed products and proprietary research-driven candidates, targeting areas of significant unmet medical need. The company is headquartered in Shanghai, China, and its shares are on both the Nasdaq and the Hong Kong Stock Exchange.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage